Role of Glypican-1 in Pancreatic Cancer
Glypican-1 在胰腺癌中的作用
基本信息
- 批准号:6615430
- 负责人:
- 金额:$ 32.72万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2003
- 资助国家:美国
- 起止时间:2003-04-01 至 2004-03-31
- 项目状态:已结题
- 来源:
- 关键词:biological signal transduction cell line chimeric proteins clinical research fibroblast growth factor gene targeting genetically modified animals growth factor receptors human tissue immunocytochemistry immunoprecipitation in situ hybridization ion exchange chromatography laboratory mouse ligands metastasis mitogen activated protein kinase neoplasm /cancer invasiveness neoplastic growth neoplastic process northern blottings pancreas neoplasms proteoglycan
项目摘要
DESCRIPTION (provided by applicant): Pancreatic ductal adenocarcinomas (PDACs) overexpress multiple tyrosine kinase receptors such as the type I FGF receptor (FGFR-1), and their ligands. Many of these ligands are heparin-binding growth factors (HBGFs), whose mitogenic actions are often dependent on interactions with heparan sulfate proteoglycans (HSPGs) that facilitate ligand binding to high affinity receptors. We have determined that PDACs overexpress glypican-1 but de not express high levels of other 5 members of the glypican family, raising the possibility that glypican-1 may have a unique and important role in PDAC. However, the exact role of glypcian-1 in PDAC and its mechanisms of action are not well understood. Therefore, we will use 4 complementary approaches to test the hypothesis that glypican-1 is of paramount importance in PDAC and that it acts by promoting mitogenesis, invasion and/or metastasis. We will first examine whether glypican-1 expression correlates with tumor grade and stage, or patient survival. Second, we will establish pancreatic cancer cell lines that overexpress glypican-1, as well as cell lines whose glypican-1 expression is suppressed by a glypican-1 antisense construct, in order to assess the role of glypican-1 in cancer cell growth, invasion, and metastasis in appropriate in vitro and in vivo model systems. Third, we will determine whether any tumorigenic effects of glypican-1 are enhanced by the presence of the type I fibroblast growth factor receptor (FGFR-1), since this receptor is overexpressed in PDAC and is activated by multiple HBGFs. To this end, we will transfect cultured human pancreatic ductal cells with cDNAs encoding glypican-1 in the absence or presence of the two major FGFR-1 isoforms. Fourth, we will explore the mechanisms whereby glypican-1 confers a growth advantage to cultured pancreatic cancer cells by examining its glycanation status and its interactions with FGFR complexes, and by engineering various glypican-1 chimeric proteins and comparing their actions with the actions of wild type glypican-1. Together, these studies will help to elucidate the role of glypican-1 in PDAC.
描述(由申请人提供):胰腺导管腺癌(pdac)过度表达多种酪氨酸激酶受体,如I型FGF受体(FGFR-1)及其配体。这些配体中有许多是肝素结合生长因子(HBGFs),其有丝分裂作用通常依赖于与硫酸肝素蛋白聚糖(HSPGs)的相互作用,后者促进配体与高亲和力受体的结合。我们已经确定,PDAC过表达glypican-1,但其他5个glypican家族成员的表达水平不高,这表明glypican-1可能在PDAC中具有独特而重要的作用。然而,glypcian-1在PDAC中的确切作用及其作用机制尚不清楚。因此,我们将使用4种互补的方法来验证glypican-1在PDAC中至关重要的假设,以及它通过促进有丝分裂、侵袭和/或转移而起作用。我们将首先检查glypican-1表达是否与肿瘤分级、分期或患者生存率相关。其次,我们将建立过表达glypican-1的胰腺癌细胞系,以及glypican-1表达被glypican-1反义结构抑制的细胞系,以便在适当的体外和体内模型系统中评估glypican-1在癌细胞生长、侵袭和转移中的作用。第三,我们将确定glypican-1的致瘤作用是否会因I型成纤维细胞生长因子受体(FGFR-1)的存在而增强,因为该受体在PDAC中过表达,并被多个hbgf激活。为此,我们将在缺乏或存在两种主要FGFR-1亚型的情况下,用编码glypican-1的cdna转染培养的人胰腺导管细胞。第四,我们将通过检测glypican-1的糖基化状态及其与FGFR复合物的相互作用,以及通过设计各种glypican-1嵌合蛋白并将其作用与野生型glypican-1的作用进行比较,探索glypican-1赋予培养胰腺癌细胞生长优势的机制。总之,这些研究将有助于阐明glypican-1在PDAC中的作用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Murray Korc其他文献
Murray Korc的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Murray Korc', 18)}}的其他基金
Role of microRNAs in genetic mouse models of pancreatic cancer
microRNA在胰腺癌遗传小鼠模型中的作用
- 批准号:
7750587 - 财政年份:2009
- 资助金额:
$ 32.72万 - 项目类别:
Role of microRNAs in genetic mouse models of pancreatic cancer
microRNA在胰腺癌遗传小鼠模型中的作用
- 批准号:
7614143 - 财政年份:2009
- 资助金额:
$ 32.72万 - 项目类别:
microRNAs as novel Biomarkers for Pancreatic Ductal Adenocarcinoma
microRNA 作为胰腺导管腺癌的新型生物标志物
- 批准号:
7663739 - 财政年份:2008
- 资助金额:
$ 32.72万 - 项目类别:
microRNAs as novel Biomarkers for Pancreatic Ductal Adenocarcinoma
microRNA 作为胰腺导管腺癌的新型生物标志物
- 批准号:
7535727 - 财政年份:2008
- 资助金额:
$ 32.72万 - 项目类别:
Role of Neuropillins in Pancreatic Cancer
Neuropilins 在胰腺癌中的作用
- 批准号:
7115757 - 财政年份:2003
- 资助金额:
$ 32.72万 - 项目类别:
Role of Neuropillins in Pancreatic Cancer
Neuropilins 在胰腺癌中的作用
- 批准号:
7258440 - 财政年份:2003
- 资助金额:
$ 32.72万 - 项目类别:
Role of Neuropillins in Pancreatic Cancer
Neuropilins 在胰腺癌中的作用
- 批准号:
6937078 - 财政年份:2003
- 资助金额:
$ 32.72万 - 项目类别:
相似海外基金
Establishment of a Mouse NK Cell Line for Analyzing Tumor Infiltration Processes and Developing a Preclinical Model for Cancer Immunotherapy.
建立小鼠 NK 细胞系,用于分析肿瘤浸润过程并开发癌症免疫治疗的临床前模型。
- 批准号:
23K06731 - 财政年份:2023
- 资助金额:
$ 32.72万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Proof of usefulness of PDX derived cell line
PDX 衍生细胞系的有用性证明
- 批准号:
23K06616 - 财政年份:2023
- 资助金额:
$ 32.72万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
A novel producer cell line for more efficient manufacturing of viral vector systems
用于更有效地制造病毒载体系统的新型生产细胞系
- 批准号:
10597799 - 财政年份:2023
- 资助金额:
$ 32.72万 - 项目类别:
Genestorian: a web application to document and trace genetic modifications in model organism and cell line collections.
Genestorian:一个网络应用程序,用于记录和追踪模型生物和细胞系集合中的遗传修饰。
- 批准号:
EP/Y024591/1 - 财政年份:2023
- 资助金额:
$ 32.72万 - 项目类别:
Fellowship
AI-Aided Tool for Day Zero Selection of High Performing Cells for Biopharma Cell Line Development
用于生物制药细胞系开发的高性能细胞零日选择的人工智能辅助工具
- 批准号:
10672364 - 财政年份:2022
- 资助金额:
$ 32.72万 - 项目类别:
Developing a stable cell line expressing recombinant sclerostin
开发表达重组硬化素的稳定细胞系
- 批准号:
10385037 - 财政年份:2022
- 资助金额:
$ 32.72万 - 项目类别:
Development of Natural Killer (NK) Cell Line-Derived Extracellular Vesicles as a New Treatment for Cancer
开发自然杀伤 (NK) 细胞系衍生的细胞外囊泡作为癌症的新治疗方法
- 批准号:
10383462 - 财政年份:2022
- 资助金额:
$ 32.72万 - 项目类别:
A cell culture management platform to improve biomedical reproducibility by combining cell line tracking, low-cost genetic analysis, and riskassessment
细胞培养管理平台,通过结合细胞系追踪、低成本遗传分析和风险评估来提高生物医学重现性
- 批准号:
10483063 - 财政年份:2022
- 资助金额:
$ 32.72万 - 项目类别:
AI-Aided Tool for Day Zero Selection of High Performing Cells for Biopharma Cell Line Development
用于生物制药细胞系开发的高性能细胞零日选择的人工智能辅助工具
- 批准号:
10546865 - 财政年份:2022
- 资助金额:
$ 32.72万 - 项目类别:
Modulating expression of candidate genes to improve lentiviral vector production in stable cell line
调节候选基因的表达以提高稳定细胞系中慢病毒载体的产量
- 批准号:
2752732 - 财政年份:2022
- 资助金额:
$ 32.72万 - 项目类别:
Studentship